Floatz logo

Romidepsin

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Yazeed Sawalha
Phase 2B
Cyclophosphamide
Mayo Clinic
Phase 2B
Inno-206
Rutgers, The State University of New Jersey
Phase 2B
ETOPOSIDE
David Bond, MD
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2B

View all 39 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →